Ulevostinag is under clinical development by Merck and currently in Phase I for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase I drugs for Cutaneous T-Cell Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ulevostinag’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ulevostinag overview
Ulevostinag (MK-1454) is under development for the treatment of hepatocellular carcinoma, anaplastic thyroid cancer, head and neck squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, or larynx and lymphomas including cutaneous T cell lymphoma. It is a synthetic cyclic dinucleotide. It is administered through intratumoral route. The drug candidate acts by targeting the stimulator of interferon genes (STING) protein. It was under development for pancreatic cancer, colorectal cancer.
The drug candidate was under development for the treatment of recurrent head and neck cancer squamous cell carcinoma, triple negative breast cancer.
Merck overview
Merck is a biopharmaceutical company with focus on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for the treatment of cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes, among others. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is headquartered in Rahway, New Jersey, the US.
For a complete picture of Ulevostinag’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
